(Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 3, 2010, Pages 277-282

  Matavelli, Luis C ^a   Huang, Jiqian ^a   Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cytokines; Diabetic nephropathy; Prorenin receptor; Renin angiotensin system

Indexed keywords

ANTIDIABETIC AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; PRORENIN RECEPTOR; PRORENIN RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; INTERSTITIAL FLUID; MALE; MICROALBUMINURIA; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; URINE VOLUME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; INFLAMMATION; INTERLEUKIN-1BETA; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77649171183     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05292.x     Document Type: Article

References (36)

1. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007 49 (Suppl. 2 S12 154.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993 329 : 1456 1462.
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 869. (Pubitemid 34940825)
4. Siragy HM, Awad A, Abadir P, Webb R. The angiotensin II Type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003 144 : 2229 2233.
5. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008 19 : 433 442.
6. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002 109 : 1417 1427.
7. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: A review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008 93 : 557 563.
8. Batenburg WW, Krop M, Garrelds IM et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J. Hypertens. 2007 25 : 2441 2453.
9. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006 69 : 105 113.
10. Ichihara A, Sakoda M, Mito-Kurauchi A, Narita T, Kinouchi K, Itoh H. Drug discovery for overcoming chronic kidney disease (CKD): New therapy for CKD by a (pro)renin-receptor-blocking decoy peptide. J. Pharmacol. Sci. 2009 109 : 20 3.
11. Suzuki F, Hayakawa M, Nakagawa T et al. Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J. Biol. Chem. 2003 278 : 22 217 22.
12. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J. Clin. Invest. 2004 114 : 1128 1135.
13. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. 'Decoy peptide' region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int. J. Mol. Med. 2009 24 : 83 9.
14. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II Type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2006 17 : 1950 1961.
15. Takahashi H, Ichihara A, Kaneshiro Y et al. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J. Am. Soc. Nephrol. 2007 18 : 2054 2061.
16. 1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens. Res. 2004 27 : 129 135.
17. Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin Type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II Type 1 receptor-blocked rat. Hypertension 2006 47 : 537 544.
18. 1 receptor blockade. J. Hypertens. 2004 22 : 1571 1577.
19. Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005 45 : 133 137.
20. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003 64 : 1208 1213.
21. 1 receptor and NADPH oxidase activity. Exp. Physiol. 2008 93 : 709 714.
22. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 2003 14 : 274 281.
23. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 1985 312 : 1412 1417.
24. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc. Nephrol. 1999 10 : 2382 2391.
25. Wilkinson-Berka JL. Prorenin and the (pro)renin receptor in ocular pathology. Am. J. Pathol. 2008 173 : 1591 1594.
26. Schefe JH, Menk M, Reinemund J et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. 2006 99 : 1355 1366.
27. Onozato ML, Toji A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy. Effects of ACEI and ARB. Kidney Int. 2002 61 : 186 194.
28. 1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes. Role of the AT1 receptor and NADPH oxidase. Hypertension 2003 42 : 206 212.
29. Satofuka S, Ichihara A, Nagai N et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009 58 : 1625 1633.
30. Kalender B, Oztürk M, Tunçdemir M et al. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem. 2002 104 : 123 130.
31. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. The inflammatory process in Type 2 diabetes. The role of cytokines. Ann. NY Acad. Sci. 2006 1084 : 89 117.
32. Hasegawa G, Nakano K, Sawada M et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991 40 : 1007 1012.
33. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008 51 : 682 688.
34. Sakoda M, Ichihara A, Kaneshiro Y et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens. Res. 2007 30 : 1139 1146.
35. Saris JJ, 't Hoen PA, Garrelds IM et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006 48 : 564 571.
36. He M, Zhang L, Shao Y et al. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 2009 606 : 155 161.